These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24462374)

  • 1. Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer.
    Thomson D; Charnley N; Parikh O
    Eur J Cancer; 2014 Mar; 50(5):1040-1. PubMed ID: 24462374
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.
    Lorente D; Bianchini D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; De Bono JS
    Eur J Cancer; 2014 Mar; 50(5):1042-3. PubMed ID: 24433842
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
    Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS
    Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
    Schrader AJ; Boegemann M; Ohlmann CH; Schnoeller TJ; Krabbe LM; Hajili T; Jentzmik F; Stoeckle M; Schrader M; Herrmann E; Cronauer MV
    Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.
    Pal SK; Sartor O
    Nat Rev Clin Oncol; 2014 Sep; 11(9):504-6. PubMed ID: 25073005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards random sequencing or precision medicine in castration-resistant prostate cancer?
    Loriot Y; Fizazi K
    Eur Urol; 2014 Jan; 65(1):37-8. PubMed ID: 24075577
    [No Abstract]   [Full Text] [Related]  

  • 7. How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.
    Francini E; Roviello G
    Tumour Biol; 2014 Aug; 35(8):7391-2. PubMed ID: 24874054
    [No Abstract]   [Full Text] [Related]  

  • 8. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
    Pal SK; Lewis B; Sartor O
    Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is in vitro-acquired resistance to enzalutamide a useful model?
    Buonerba C; Di Lorenzo G
    Future Oncol; 2014 Dec; 10(16):2551-3. PubMed ID: 25531044
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment sequencing in metastatic castrate-resistant prostate cancer.
    Sartor O; Gillessen S
    Asian J Androl; 2014; 16(3):426-31. PubMed ID: 24675654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring].
    Miller K; Albers P; Eichenauer R; Geiges G; Grimm MO; König F; Mickisch G; Pfister D; Schwentner C; Suttmann H; Zastrow S
    Urologe A; 2014 May; 53(5):710-4. PubMed ID: 24806804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    Shiota M; Yokomizo A
    Eur Urol; 2016 Mar; 69(3):e41-2. PubMed ID: 26215602
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer: Enzalutamide--differential cross resistance with taxanes.
    Fenner A
    Nat Rev Urol; 2015 Feb; 12(2):64. PubMed ID: 25534993
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
    Lu K
    Eur Urol; 2015 Dec; 68(6):e129-31. PubMed ID: 26318711
    [No Abstract]   [Full Text] [Related]  

  • 16. New agents in the arsenal to fight castrate-resistant prostate cancer.
    Ezzell EE; Chang KS; George BJ
    Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
    Caffo O; Maines F; Veccia A
    Eur Urol; 2015 Dec; 68(6):e132-3. PubMed ID: 26320376
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    van Soest RJ; de Morrée ES; Kweldam CF; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur Urol; 2016 Mar; 69(3):e43-4. PubMed ID: 26233533
    [No Abstract]   [Full Text] [Related]  

  • 19. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer.
    Sartor O; Dong Y
    Asian J Androl; 2015; 17(3):439-40. PubMed ID: 25532583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.